•
Mar 31, 2022
Humacyte Q1 2022 Earnings Report
Announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.
Key Takeaways
Humacyte reported first quarter 2022 financial results, with revenue of $233 thousand and a net loss of $19.8 million. The company's cash, cash equivalents, and short-term investments totaled $206.2 million as of March 31, 2022, which is expected to fund operations through the end of 2024.
HAVs were shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries.
Shamik Parikh M.D., was appointed as Chief Medical Officer.
Multiple scientific meeting presentations and publications highlighted clinical and preclinical HAV data.
Cash, cash equivalents and short-term investments of $206.2 million as of March 31, 2022.